NEW YORK, October 10, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) investigates claims on behalf of investors of Barclays PLC (“Barclays” or the “Company”) UCS. A class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Barclays American Depositary Receipts (“ADRs”) between February 18, 2021 and March 25, 2022 inclusive (the “Collection Period”).

If you have purchased ADRs from Barclays during class time and would like to discuss our investigation, please contact us via email [email protected] or by calling (646) 315-9003 or our toll-free number 1-800-290-1952.

If you are a member of the proposed class, you can move the court by November 22, 2022 at the latest to serve as lead plaintiff for the alleged class. You do not have to seek lead plaintiff to participate in a possible recovery.

According to the complaint, on March 28, 2022, Barclays issued a press release announcing that Barclays Bank PLC (“BBPLC”) had sold $15.2 billion in unregistered securities, exceeding the $20 limit $.8 billion in securities registered pursuant to the August 2019 Shelf Registration Statement and that BBPLC would issue a tender offer.

Also on March 28, 2022, Reuters published an article entitled “Barclays faces $590 million loss, investigation for slip-up sales”. The article reads: “British bank Barclays is facing an estimated £450 million ($592 million) loss and regulatory investigation for exceeding a US limit on sales of structured products, of which some have gained popularity since the Russian invasion of Ukraine.” The article also states that “Barclays [. . .] also said on Monday that there was a proposed $1 billion share buyback.

Following the news, the price of Barclays ADRs fell $0.96 per share, or 10.6%, to close at $8.09 per share on Feb. 14.